Fig. 7: Early-stage treatment with mRho ASO1 successfully delays ONL thinning in Prph2^Y141C/+ mice.

A Representative images of retinal sections stained with H&E at P90. B–D Nuclear counts from 100 µm-windows at every 500 µm distance from the optic nerve and across the superior-inferior plane of retinal sections collected from P90 un-injected, 1X PBS injected as a control and mRho ASO1 injected animals following (B) early (P15) or (C) late-stage (P45) therapeutic intervention. B, C WT and Prph2^Y141C/+ controls were added for comparison. B, C ^∗P < 0.05, ^∗∗P < 0.01, ^∗∗∗P < 0.001 by two-way ANOVA (P15 Injected: Interaction P < 0.0001, Row Factor P < 0.0001, and Column Factor P < 0.0001. P45 Injected: Interaction P < 0.0001, Row Factor P < 0.0001, and Column Factor P < 0.0001. P15 vs. P45 Injected: Interaction P < 0.0001, Row Factor P < 0.0001, and Column Factor P < 0.0001.) with Tukey’s post-hoc comparison. ^*denotes comparisons between Prph2^Y141C/+ and (B) Prph2^Y141C/+ 3.125 µg ASO or (C) Prph2^Y141C/+ 6.25 µg ASO. ^#denotes comparisons between (B) Prph2^Y141C/+ 3.125 µg ASO and P15 injected Prph2^Y141C/+ 1X PBS. D Plotted are mean ± SD values from (B) and (C) for WT, Prph2^Y141C/+ P15 Injected 3.125 µg ASO, and P45 injected 6.25 µg ASO Prph2^Y141C/+ for ease of comparison. ⁺ denotes comparisons P15 injected and P45 injected. N = 3 animals for all genotypes and experimental conditions. Scale bar corresponds to 50 µm.